Grufity logoGrufity logo

BEAM

44.28USD-1.42(-3.11%)Market Closed

Beam Therapeutics Inc.

Market Summary

USD44.28-1.42Market Closed
-3.11%

BEAM Alerts

BEAM Stock Price

RSI Chart

Valuation

Market Cap

3.4B

Price/Earnings

-14.65

Price/Sales

59.51

Price/Cashflow

20.05

Price/Sales

Profitability

Return on Equity

-29.24%

Return on Assets

-16.5%

Fundamentals

Revenue

Revenue Y/Y

153.11%

Revenue Q/Q

-5.12%

Earnings

Earnings (TTM)

-315.4M

Earnings Y/Y

-289.7%

Earnings Q/Q

-52.29%

Price Action

52 Week Range

88.18
(Low)(High)

Last 7 days

-5.5%

Last 30 days

-6.9%

Last 90 days

-21.3%

Trailing 12 Months

-45.9%

Financial Health

Current Ratio

5.56

Debt/Equity

2.45

Debt/Cashflow

-0.03

Investor Care

Shares Dilution (1Y)

3.42%

Diluted EPS (TTM)

-4.5

Peers (Alternatives to Beam Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
7.14% 43.50%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
21.80% 28.96%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
24.23% -35.48%
4.2
2.57
227.55% 302.16%
41.3B
10.4B
8.82% 22.00%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
7.16% 39.03%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
7.23% -37.09%
-12.87
32.5
-41.50% -607.58%
3.4B
-
-6.88% -45.94%
-14.65
59.51
215916.67% 21.41%
2.1B
68.3M
-4.89% -63.56%
-8.33
30.98
42.18% -19.70%
2.0B
432.8M
-5.28% -44.88%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
1.8B
-27.49% -91.73%
-1.22
1.39
53.41% -22.97%
1.6B
69.7M
-21.14% -78.94%
-3.15
20.84
745.14% -7.72%
891.0M
3.2M
12.62% -35.50%
-6.7
275.59
11.14% -46.59%
692.0M
114.2M
-18.16% -60.18%
-4.02
6.06
-17.11% -27.41%
458.1M
-
-23.83% -90.20%
-13.56
44.06
522.71% -129.91%
218.9M
-
-24.71% -82.02%
-2.36
609.63
-71.03% -64.56%

Financials for Beam Therapeutics

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
RevenueNaN%nullnullnull5239
Operating Expenses10.0%405368329444371
  S&GA Expenses7.9%8377665748
  R&D Expenses10.5%322291262387323
Net Income-34.8%-315.45-233.99-238.29-370.64-401.39
* denotes actual numbers (not divided by Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-4.8%1,3501,4181,4531,4741,157
  Current Assets-6.0%1,1091,1801,2391,273941
    Cash Equivalents-41.1%157266297560612
  Net PPE4.8%111106948472
Liabilities2.8%636618624648303
  Current Liabilities12.5%239212219213101
Shareholder's Equity-10.7%714800829827854
  Retained Earnings-12.0%-1,019.01-909.44-837.49-768.27-703.60
  Additional Paid-In Capital1.4%1,7371,7131,6691,5941,557
Accumulated Depreciation15.3%2623191614
Shares Outstanding0.2%7070706868
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-45.3%94171191-66.27-92.40
  Share Based Compensation13.6%7768574435
Cashflow From Investing-20.8%-652.27-539.98-551.86-294.14-298.07
Cashflow From Financing-75.9%101420559756865

Risks

What is the probability of a big loss on BEAM?

66.2%


Probability that Beam Therapeutics stock will be more than 20% underwater in next one year

56.5%


Probability that Beam Therapeutics stock will be more than 30% underwater in next one year.

40.8%


Probability that Beam Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BEAM drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Beam Therapeutics was unfortunately bought at previous high price.

Returns

Cumulative Returns on BEAM

-1.6%


10-Year Cumulative Returns

What are the long-term rolling returns for BEAM?

FIve years rolling returns for Beam Therapeutics.

Which funds bought or sold BEAM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
Capital Impact Advisors, LLC
-
-
208,000
554,000
0.55%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
650,000
3,500,000
0.01%
2022-11-16
GLENMEDE TRUST CO NA
NEW
-
216,000
216,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-44,000
-
-%
2022-11-15
MERCER GLOBAL ADVISORS INC /ADV
NEW
-
223,000
223,000
-%
2022-11-15
Alphabet Inc.
UNCHANGED
-
2,872,000
15,321,000
0.78%
2022-11-15
JANE STREET GROUP, LLC
SOLD OFF
-100
-3,023,000
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
STATE STREET CORP
REDUCED
-23.2
-7,076,000
122,073,000
0.01%
2022-11-15
Clearstead Advisors, LLC
UNCHANGED
-
-
1,000
-%

1–10 of 42

Latest Funds Activity

Are funds buying BEAM calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own BEAM

Beam Therapeutics News

The Motley Fool

A Sitcom Character Inspired This Investor.36 hours ago

BEAM Fair Value

Recent SEC filings of Beam Therapeutics

View All Filings
Date Filed Form Type Document
Nov 07, 2022
10-Q
Quarterly Report
Nov 07, 2022
8-K
Current Report
Nov 02, 2022
4
Insider Trading
Sep 08, 2022
4
Insider Trading
Sep 07, 2022
8-K
Current Report
Sep 02, 2022
4
Insider Trading
Sep 02, 2022
4
Insider Trading
Sep 02, 2022
4
Insider Trading
Sep 02, 2022
4
Insider Trading
Sep 02, 2022
4
Insider Trading

Latest Insider Trading transactions for BEAM

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-10-31
Evans John M.
SOLD
-1,389,230
46.3075
-30,000
CEO
2022-10-31
Evans John M.
SOLD
-927,203
46.3602
-20,000
CEO
2022-09-06
FMR LLC
ACQUIRED
-
-
551
-
2022-09-06
FMR LLC
SOLD
-
-
-25,620
-
2022-09-06
FMR LLC
SOLD
-29,891.8
54.25
-551
-
2022-08-05
FMR LLC
SOLD
-1,219,620
60.5
-20,159
-
2022-08-05
FMR LLC
SOLD
-10,187
61
-167
-
2022-08-04
FMR LLC
ACQUIRED
-
-
375,536
-
2022-08-04
FMR LLC
SOLD
-
-
-800,000
-
2022-08-04
FMR LLC
SOLD
-
-
-375,369
-

1–10 of 50

John Evans
340
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

BEAM Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
License and collaboration revenue$ 15,799$ 763$ 40,883$ 775
Revenue, Product and Service [Extensible List]us-gaap:LicenseMemberus-gaap:LicenseMemberus-gaap:LicenseMemberus-gaap:LicenseMember
Operating expenses:    
Research and development$ 85,287$ 54,623$ 225,253$ 290,306
General and administrative21,81515,77465,12439,450
Total operating expenses107,10270,397290,377329,756
Loss from operations(91,303)(69,634)(249,494)(328,981)
Other income (expense):    
Change in fair value of derivative liabilities(4,900)35,80020,900(8,400)
Change in fair value of non-controlling equity investments10,431(4,892)(1,378)21,960
Change in fair value of contingent consideration liabilities(875)10,599(543)9,553
Interest and other income (expense), net4,98297,686(63)
Total other income (expense)9,63841,51626,66523,050
Net loss before income taxes(81,665)(28,118)(222,829)(305,931)
Provision for income taxes(2,410)0(2,410)0
Loss from equity method investment(25,500) (25,500) 
Net loss(109,575)(28,118)(250,739)(305,931)
Unrealized gain (loss) on marketable securities(484)(12)(4,624)28
Comprehensive loss$ (110,059)$ (28,130)$ (255,363)$ (305,903)
Net loss per common share, basic$ (1.56)$ (0.42)$ (3.59)$ (4.86)
Net loss per common share, diluted$ (1.56)$ (0.42)$ (3.59)$ (4.86)
Weighted-average common shares outstanding, basic70,343,19666,377,61169,758,43462,960,219
Weighted-average common shares outstanding, diluted70,343,19666,377,61169,758,43462,960,219

BEAM Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 156,511$ 559,994
Marketable securities938,043405,653
Collaboration receivable 300,000
Prepaid expenses and other current assets14,3587,360
Total current assets1,108,9121,273,007
Property and equipment, net111,18084,258
Restricted cash12,75012,746
Operating lease right-of-use assets115,534102,718
Other assets1,8741,724
Total assets1,350,2501,474,453
Current liabilities:  
Accounts payable7,0247,474
Accrued expenses and other current liabilities38,60028,921
Accrued sub-license fees 38,743
Derivative liabilities21,30042,200
Current portion of deferred revenue159,90286,270
Current portion of lease liability9,8237,540
Current portion of equipment financing liability2,2102,287
Total current liabilities238,859213,435
Long-term lease liability165,075134,810
Long-term equipment financing liability1,3883,007
Contingent consideration liabilities31,91031,367
Long-term portion of deferred revenue198,288262,303
Other liabilities2532,793
Total liabilities635,773647,715
Commitments and contingencies (See Note 7, Leases, Note 10, License agreements and Note 11, Collaboration and license agreements)
Stockholders’ equity:  
Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at September 30, 2022 and December 31, 2021, respectively
Common stock, $0.01 par value; 250,000,000 shares authorized, 70,468,614 and 68,581,251 issued, and 70,457,676 and 68,389,425 outstanding at September 30, 2022 and December 31, 2021, respectively705684
Additional paid-in capital1,737,4591,594,378
Accumulated other comprehensive (loss) income(4,674)(50)
Accumulated deficit(1,019,013)(768,274)
Total stockholders’ equity714,477826,738
Total liabilities and stockholders equity$ 1,350,250$ 1,474,453